Comparison of Efficacy and Safety of Insulin Detemir Once or Twice Daily in a Basal-Bolus Regimen With Insulin Aspart in Patients With Type 1 Diabetes.

Trial Profile

Comparison of Efficacy and Safety of Insulin Detemir Once or Twice Daily in a Basal-Bolus Regimen With Insulin Aspart in Patients With Type 1 Diabetes.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Insulin detemir (Primary) ; Insulin aspart
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ADAPT
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Jul 2009 Actual end date (Oct 2006) added as reported by ClinicalTrials.gov.
    • 08 Apr 2009 Additional lead trial centre and investigator identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top